Sionna Therapeutics, Inc. (SION)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized loss on marketable securities | -118 | |||
| Total other comprehensive loss | -118 | |||
| Research and development | 15,383 | |||
| General and administrative | 6,523 | |||
| Total operating expenses | 21,906 | |||
| Loss from operations | -21,906 | |||
| Other income | 171 | |||
| Interest income | 3,667 | |||
| Total other income | 3,838 | |||
| Net loss | -18,068 | |||
| Comprehensive loss | -18,186 | |||
| Net loss per share, basic (in dollars per share) | -410 | |||
| Net loss per share, diluted (in dollars per share) | -410 | |||
| Weighted-average number of common shares outstanding, basic (in shares) | 44,116,997 | |||
| Weighted-average number of common shares outstanding, diluted (in shares) | 44,116,997 | |||